Latest Studies And Clinical Trials Lead To Compelling Developments Indicating Cannabinoids… — Coral Springs, Florida, December 16, 2015 /prnewswire/ —

PR Newswire company specializing in the development of cannabis-based medicines, announced that it has entered into a comprehensive clinical drug development to focus on delivering GMP quality pre-clinical data to enable entry of CS-NEURO-1 into a Phase I human study in Europe with ImmunoClin (OTC: IMCL). After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe. Read the full Cannabis Science (CBIS) Press Release & Bonus Coverage at: Additional Cannabis Science coverage issued by : As the door begins to close on 2015, investors seeking to build a strong foundation for 2016 will want to take a glance back at the most relevant industries heading into the new year, and to make moves accordingly. Small cap biostocks in particular made strides over the last couple of financial quarters, with Cannabis Science, Inc. (CBIS) standing out in recent weeks with several key distribution and development moves. On Tuesday, Cannabis Science announced that it has entered into partnership with ImmunoClin (IMCL) to oversee all aspects of a new clinical research program for Cannabis Science. The intent with this program will be to place an emphasis on GMP quality pre-clinical data, a process that will include cultivation, formulation, and manufacturing of various strains of clinical grade cannibinoid products.

To read more visit–conditions-562628081.html

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report